No Data
No Data
The Past Three Years for Ligand Pharmaceuticals (NASDAQ:LGND) Investors Has Not Been Profitable
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals
Merck (MRK) said late Monday that it has received approval from the US Food and Drug Administration for Capvaxive to prevent invasive pneumococcal disease and pneumococcal pneumonia among adults. Liga
Express News | FDA Approves CAPVAXIVE, Sixth Product Using Pfenex Expression Technology; Ligand Pharmaceuticals Entitled To Royalties On Global Sales
Express News | Ligand Pharmaceuticals Inc: Ligand Is Entitled to a Royalty on Worldwide Net Sales of Capvaxive
Express News | Ligand Collaborator Merck Receives FDA Approval for Capvaxive™ (Pneumococcal 21-Valent Conjugate Vaccine) for Adults
Express News | FDA: Approved Merck's Bla for Pneumococcal 21-Valent Conjugate Vaccine Effective July 17
No Data